IRIS
PALA, Daniele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.476
AS - Asia 1.976
EU - Europa 1.479
SA - Sud America 233
AF - Africa 116
Continente sconosciuto - Info sul continente non disponibili 96
OC - Oceania 1
Totale 6.377
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.405
SG - Singapore 645
CN - Cina 585
FI - Finlandia 319
VN - Vietnam 316
IT - Italia 263
IE - Irlanda 245
SE - Svezia 227
BR - Brasile 181
DE - Germania 137
HK - Hong Kong 133
TR - Turchia 83
FR - Francia 79
ZA - Sudafrica 74
BD - Bangladesh 54
NL - Olanda 50
GB - Regno Unito 46
IN - India 35
CA - Canada 30
AR - Argentina 25
BE - Belgio 23
MX - Messico 23
CI - Costa d'Avorio 22
UA - Ucraina 21
JP - Giappone 17
IQ - Iraq 14
RU - Federazione Russa 13
PH - Filippine 12
ES - Italia 11
ID - Indonesia 11
JO - Giordania 9
MA - Marocco 8
PK - Pakistan 8
TH - Thailandia 8
CZ - Repubblica Ceca 7
LT - Lituania 7
VE - Venezuela 7
AL - Albania 5
CO - Colombia 5
EC - Ecuador 5
HU - Ungheria 5
PL - Polonia 5
CL - Cile 4
IL - Israele 4
NP - Nepal 4
PS - Palestinian Territory 4
SA - Arabia Saudita 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
AZ - Azerbaigian 3
BO - Bolivia 3
HN - Honduras 3
KE - Kenya 3
KR - Corea 3
MY - Malesia 3
PY - Paraguay 3
TN - Tunisia 3
TW - Taiwan 3
AO - Angola 2
CR - Costa Rica 2
JM - Giamaica 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LV - Lettonia 2
MD - Moldavia 2
NI - Nicaragua 2
OM - Oman 2
QA - Qatar 2
RO - Romania 2
SN - Senegal 2
SV - El Salvador 2
UZ - Uzbekistan 2
AM - Armenia 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
CH - Svizzera 1
CU - Cuba 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
ET - Etiopia 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
LK - Sri Lanka 1
NO - Norvegia 1
PA - Panama 1
PR - Porto Rico 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TV - Tuvalu 1
VG - Isole Vergini Britanniche 1
Totale 6.282
Salva come PNG Salva come JPEG
Città #
Singapore 344
Ashburn 330
Dublin 245
Chandler 238
San Jose 221
Santa Clara 191
Beijing 144
Dallas 144
Parma 131
Hong Kong 122
Ho Chi Minh City 99
Dearborn 82
Hanoi 78
Izmir 71
Johannesburg 71
Boardman 69
Ann Arbor 66
Nanjing 63
Council Bluffs 58
Los Angeles 57
New York 52
Shanghai 50
Bremen 42
Princeton 42
Jacksonville 38
Lauterbourg 38
Munich 37
Wilmington 35
Helsinki 25
Washington 25
Abidjan 22
Brussels 21
Columbus 21
San Mateo 21
Kunming 19
Shenyang 19
São Paulo 16
Buffalo 15
Düsseldorf 15
Hebei 15
Hefei 15
Tokyo 15
Nanchang 14
Seattle 13
Toronto 13
Turku 13
Jinan 12
Guangzhou 11
Haiphong 11
Jiaxing 11
Moscow 11
Changsha 10
Da Nang 10
London 10
Orem 10
Phoenix 10
Atlanta 9
Chennai 9
Hangzhou 9
Mexico City 9
Milan 9
Montreal 9
Amman 8
Denver 8
Modena 8
Rio de Janeiro 8
Springfield 8
Tianjin 8
Belo Horizonte 7
Boston 7
Brooklyn 7
Jakarta 7
Norwalk 7
Pune 7
Rome 7
Stockholm 7
The Dalles 7
Woodbridge 7
Can Tho 6
Ninh Bình 6
Poplar 6
San Francisco 6
Bangkok 5
Chicago 5
Fremont 5
Grafing 5
Houston 5
Porto Alegre 5
Zhengzhou 5
Ankara 4
Baghdad 4
Borås 4
Brasília 4
Brescia 4
Curitiba 4
Fuzhou 4
Haikou 4
Hyderabad 4
Lahore 4
New Delhi 4
Totale 3.856
Salva come PNG Salva come JPEG
Nome #
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 248
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 233
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 225
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 218
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 213
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 212
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 209
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 193
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 188
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 178
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 167
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 166
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 165
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 161
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 159
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 155
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 154
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 154
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 153
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 151
Target-hopping: a useful approach to identify novel Eph receptor antagonists 148
ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors 148
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 147
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 144
Computer-Aided Design of Novel Antagonists of the EphA2 Receptor 144
Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL 143
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 142
Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration 138
Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines 138
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 137
New classes of potent heparanase inhibitors from ligand-based virtual screening 131
Homology models of melatonin receptors: challenges and recent advances. 125
Synthesis and characterization of new bivalent agents as melatonin- and histamine h3-ligands. 111
Synthesis of (E)-8-(3-chlorostyryl)caffeine analogs leading to 9-deazaxanthine derivatives as dual A2A antagonists /MAO-B inhibitors. 108
Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists. 104
Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. 98
In vitro and in vivo efficacy of an orally bioavailable antagonist of Eph-ephrin system in tumor angiogenesis and growth 93
Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties 92
Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase 92
Synthesis, structure and inhibitory activity of a stereoisomer of oseltamivir carboxylate 91
MT1-Selective Melatonin Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Dynamics Investigation of N-[[(3-O-Substituted)anilino]alkyl]amides. 87
Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014) 82
Application of comparative modelling to the design and discovery of novel GPCR ligands 32
Totale 6.377
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.790
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.790
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022173 0 0 0 28 2 7 8 25 7 14 16 66
2022/2023891 99 107 39 60 103 97 14 48 299 2 21 2
2023/2024288 16 27 4 13 21 61 36 24 8 14 24 40
2024/2025994 26 64 61 55 120 109 49 45 132 76 97 160
2025/20262.318 212 269 235 188 291 132 260 74 332 167 94 64
2026/2027396 46 102 106 142 0 0 0 0 0 0 0 0
Totale 6.377